Abstract
Aim: The aim of the study was to investigate hypoglycemic and hypolipidemic activities of aqueous extracts of Centaurium erythraea (CnE) and Ajuga iva (AjI) after daily oral dosing for 60 days in a rodent model of metabolic syndrome (MetS).
Materials and Methods: Meriones shawi rats were fed a high caloric diet and forced to limited physical activity for 180 days to develop obesity, hyperglycemia and hyperlipidemia (OHH) as a model of MetS. After administration of single oral doses of test substances [extracts of CnE (250 mg/kg) and AjI (150 mg/kg), and reference drug [glibenclamide (GLB; 3 mg/kg)] to OHH rats, plasma levels of glucose, insulin, Total Cholesterol (TC), and Triglycerides (TG) were measured. In the sub-chronic study, the effect of daily oral dosing of test substances for 60 days to OHH rats, on Body Weight (BW), plasma glucose, insulin, TC, Low Density Lipoprotein (LDL)-cholesterol, High Density Lipoprotein (HDL)-cholesterol, TG, and free fatty acids were determined; insulin resistance (IR as HOMA-IR and QUICKI) and atherosclerotic index were calculated. Results and Conclusion: Meriones shawi rats developed OHH, hyperinsulinemia, IR and dyslipidemia- typical components of MetS. Single doses of test substances decreased only hyperglycemia. In the sub-chronic study, the test substances reduced plasma glucose, insulin, TC and LDL-cholesterol, as well as HOMA-IR and atherosclerotic index (AjI-extract > CnE-extract > GLB); plasma level of TG decreased with AjI only. These two plants may have the potential to be used therapeutically in the treatment of diabetes and possibly MetS, since, previous toxicological studies have shown a wide margin of safety for AjI and CnE.Keywords: Ajuga iva, Centaurium erythraea, diabetes, hypoglycemia, hypolipidemia, insulin resistance, Meriones shawi.
The Natural Products Journal
Title:Hypoglycemic and Hypolipidemic Effects of Aqueous Extracts of Ajuga iva and Centaurium erythreae on a Rodent Model of Metabolic Syndrome
Volume: 7 Issue: 1
Author(s): Adel Tahraoui, Zafar H. Israili and Badiaa Lyoussi
Affiliation:
Keywords: Ajuga iva, Centaurium erythraea, diabetes, hypoglycemia, hypolipidemia, insulin resistance, Meriones shawi.
Abstract: Aim: The aim of the study was to investigate hypoglycemic and hypolipidemic activities of aqueous extracts of Centaurium erythraea (CnE) and Ajuga iva (AjI) after daily oral dosing for 60 days in a rodent model of metabolic syndrome (MetS).
Materials and Methods: Meriones shawi rats were fed a high caloric diet and forced to limited physical activity for 180 days to develop obesity, hyperglycemia and hyperlipidemia (OHH) as a model of MetS. After administration of single oral doses of test substances [extracts of CnE (250 mg/kg) and AjI (150 mg/kg), and reference drug [glibenclamide (GLB; 3 mg/kg)] to OHH rats, plasma levels of glucose, insulin, Total Cholesterol (TC), and Triglycerides (TG) were measured. In the sub-chronic study, the effect of daily oral dosing of test substances for 60 days to OHH rats, on Body Weight (BW), plasma glucose, insulin, TC, Low Density Lipoprotein (LDL)-cholesterol, High Density Lipoprotein (HDL)-cholesterol, TG, and free fatty acids were determined; insulin resistance (IR as HOMA-IR and QUICKI) and atherosclerotic index were calculated. Results and Conclusion: Meriones shawi rats developed OHH, hyperinsulinemia, IR and dyslipidemia- typical components of MetS. Single doses of test substances decreased only hyperglycemia. In the sub-chronic study, the test substances reduced plasma glucose, insulin, TC and LDL-cholesterol, as well as HOMA-IR and atherosclerotic index (AjI-extract > CnE-extract > GLB); plasma level of TG decreased with AjI only. These two plants may have the potential to be used therapeutically in the treatment of diabetes and possibly MetS, since, previous toxicological studies have shown a wide margin of safety for AjI and CnE.Export Options
About this article
Cite this article as:
Tahraoui Adel, Israili H. Zafar and Lyoussi Badiaa, Hypoglycemic and Hypolipidemic Effects of Aqueous Extracts of Ajuga iva and Centaurium erythreae on a Rodent Model of Metabolic Syndrome, The Natural Products Journal 2017; 7 (1) . https://dx.doi.org/10.2174/2210315506666161024122601
DOI https://dx.doi.org/10.2174/2210315506666161024122601 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |
Call for Papers in Thematic Issues
Ayurvedic medicinal therapeutic approaches for inflammatory and neurodegenerative disorders
Usually, in our elderly population, neurodegenerative disorders occur due to neuron death. Alzheimer?s disease (AD) is an irreversible and progressive neurodegenerative disease. Dementia is the leading cause of AD, which affects about 30 million people worldwide. According to the World Alzheimer report 2018, a new case of dementia develops every ...read more
Recent Advances in Biotransformation of Bioactive Terpenoids using Aspergillus niger
Biotransformation is the reaction catalyzed by biological catalysts of either isolated enzymes or whole cell cultures of microorganisms. This process has been extensively applied in the conversion of bioactive terpenoids with high regio- and stereospecifity. This process has been also applied in the lead discovery and development. Aspergillus niger has ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trends in Metabolic Syndrome and Gene Networks in Human and Rodent Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy
Current Pharmacogenomics The Battle of the Sexes for Stroke Therapy: Female- Versus Male-Derived Stem Cells
CNS & Neurological Disorders - Drug Targets Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design Repeated Restraint and Nerve Growth Factor Administration in Male and Female Mice: Effect on Sympathetic and Cardiovascular Mediators of the Stress Response
Current Neurovascular Research Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Safety Aspects of Statins: Which Factors Create the Adverse Effects of Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Apoptosis in Atherosclerosis: A Mini-Review
Mini-Reviews in Medicinal Chemistry Editorial [Hot topic: Targets of Research in the Metabolic Syndrome (Guest Editor: Lindsay Brown)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Angiotensin II in the Development of Nephropathy and Podocytopathy of Diabetes
Current Diabetes Reviews Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology Optimized Trace Analysis of Verapamil in Biological Fluids Using Solvent Bar Micro Extraction Technique Coupled with HPLC-UV Detection
Current Analytical Chemistry The Management of Gestational Diabetes
Current Diabetes Reviews Effects of Static Magnetic Fields on Blood Pressure in Animals and Humans
Current Hypertension Reviews Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Current Pharmaceutical Biotechnology MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study
Current Alzheimer Research